Phase 2 OVARIO Update: Promising Survival Rates in Patients with Advanced Ovarian Cancer Treated with Niraparib plus Bevacizumab Maintenance
In the phase 2 OVARIO study, median progression-free survival has not yet been reached in women with advanced ovarian cancer who are being treated with the combination of niraparib and bevacizumab after response to first-line platinum-based chemotherapy plus bevacizumab. The combination did not appear to cause cumulative toxicities.
No Difference in PFS Between Platinum-Based Chemotherapy and Olaparib in Women with Platinum-Sensitive Ovarian Cancer
A global phase 3 randomized study is currently enrolling patients with stage III or IV high-grade nonmucinous epithelial ovarian cancer to assess the efficacy of an investigational anti–PD-1 humanized monoclonal antibody plus standard of care as first-line treatment and maintenance. The primary outcome measure is progression-free survival.
Chemotherapy-Free PARP Inhibitor Combination Improves Outcomes versus Single-Agent PARP Inhibitor in Recurrent Ovarian Cancer
Individualized Starting Dose of Niraparib Is Recommended in First-Line Maintenance Setting in Recurrent Ovarian Cancer
In the PRIMA study, patients with recurrent ovarian cancer receiving maintenance therapy with an individualized dose of niraparib had similar efficacy compared with placebo as patients receiving a fixed dose of niraparib while experiencing half as many thrombocytopenic events.
In a pooled analysis of 2 randomized trials of rucaparib for the treatment of patients with recurrent high-grade ovarian cancer, deleterious BRCA mutations were identified in 71% of patients with responses lasting at least 1 year but in only 52% of short-term responders.
Finding a Pathogenic Mutation on Genetic Testing Does Not Add to Stress or Anxiety in Women with Newly Diagnosed Ovarian Cancer
In a study of 76 English-speaking women with newly diagnosed ovarian cancer who underwent genetic testing, those found to have a pathogenic mutation did not report increased levels of stress, anxiety, or depression compared with pre-genetic testing. Those testing negative for mutations saw their posttest anxiety levels decline.
Page 1 of 5
Results 1 - 10 of 47
Results 1 - 10 of 47